-
Sep 27, 2024 | 
urologytimes.com | Benjamin H. Lowentritt |Brian Richardson |Angelo A. Baccala |Jeffrey Ferguson
September 27, 2024By The panel concludes by addressing unmet needs in prostate cancer management, with a particular focus on improving risk stratification methods. Video content above is prompted by the following question:What are some unmet needs in prostate cancer care today, particularly regarding diagnosis, risk stratification and treatment? How can these gaps be addressed to improve patient outcomes? Related Content Related Content
-
Aug 23, 2024 | 
urologytimes.com | Benjamin H. Lowentritt |Brian Richardson |Angelo A. Baccala |Jeffrey Ferguson
August 23, 2024By Medical oncologists explore risk stratification strategies for newly diagnosed patients with prostate cancer, emphasizing the significant role of the Gleason score in diagnosis and prognosis. Video content above is prompted by the following question:How do you approach risk stratification in prostate cancer patients, specifically in those newly diagnosed? (Brian Richardson, MD)Do you rely on the Gleason score, specific biomarkers, or a combination? Related Content Related Content
-
Aug 23, 2024 | 
urologytimes.com | Benjamin H. Lowentritt |Brian Richardson |Angelo A. Baccala |Jeffrey Ferguson
August 23, 2024By The key opinion leaders explore risk factors for prostate cancer, detailing both general risk groups and high-risk populations more susceptible to developing the disease. Video content above is prompted by the following question:We know that some patient populations are at a higher risk for developing prostate cancer. Please briefly discuss the general risk groups in prostate cancer. Related Content Related Content
-
Aug 16, 2024 | 
urologytimes.com | Benjamin H. Lowentritt |Brian Richardson |Angelo A. Baccala |Jeffrey Ferguson
August 16, 2024By Prostate cancer management experts share their clinical insights on selecting appropriate serum, urine, and/or tissue biomarkers, highlighting specific scenarios that warrant each type of test. Video content above is prompted by the following question:In your clinical practice, are there specific situations in which you would choose serum, urine and/or tissue biomarkers? If so, can you expand on when you might use them? Related Content Related Content
-
Aug 16, 2024 | 
urologytimes.com | Benjamin H. Lowentritt |Brian Richardson |Angelo A. Baccala |Jeffrey Ferguson
August 16, 2024By The panel emphasizes the crucial need for swift biomarker and genetic testing to facilitate timely and effective patient care in prostate cancer management. Video content above is prompted by the following question:What is the role for biomarker and genetic testing in diagnosing prostate cancer? When during the disease course do you test for biomarkers? Related Content Related Content
-
Aug 9, 2024 | 
urologytimes.com | Benjamin H. Lowentritt |Brian Richardson |Angelo A. Baccala |Jeffrey Ferguson
The key opinion leaders explore the challenges and limitations associated with using prostate-specific antigen (PSA) as a biomarker for prostate cancer detection and monitoring.
-
Aug 9, 2024 | 
urologytimes.com | Benjamin H. Lowentritt |Brian Richardson |Jeffrey Ferguson |Angelo A. Baccala
August 9, 2024By The panel of experts in prostate cancer offers a comprehensive overview of prostate cancer diagnosis, emphasizing the role of prostate-specific antigen (PSA) testing in screening for the disease. Video content above is prompted by the following:Please provide an overview on the diagnosis of prostate cancer, highlighting the NCCN Guidelines. What is the role of prostate-specific antigen (PSA) testing in prostate cancer screening? Related Content Related Content
-
Mar 15, 2024 | 
futuremedicine.com | Daniel E. Spratt |Tanya B. Dorff |Rana R. McKay |Benjamin H. Lowentritt
Prostate cancer is the most prevalent cancer in men and the second leading cause of cancer death in men in the USA. In 2023, American Cancer Society estimated 288,300 new prostate cancer cases (29% of male cancer cases), with 34,700 estimated deaths (11% of male cancer death) [1]. Prostate cancer incidence increases with increasing age, with the average age at the diagnosis time being 66 years.
-
Jan 25, 2024 | 
targetedonc.com | Benjamin H. Lowentritt
Benjamin H. Lowentritt, MD, FACS, medical director of prostate cancer, a practicing urologist at Chesapeake Urology in Baltimore, Maryland, discusses findings from a United States real-world study of patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (Erleada) or enzalutamide (Xtandi).
-
Nov 17, 2023 | 
urologytimes.com | Benjamin H. Lowentritt
For patients with prostate cancer who require therapy, micronized abiraterone provides many advantages. In this Urology Medical Perspectives series titled “Clinical Use of Micronized Abiraterone for Patients with Prostate Cancer,” Benjamin H. Lowentritt, MD, FACS, a urologist at Chesapeake Urology, discusses the role of micronized abiraterone in the treatment paradigm and provides clinical insights on incorporating it into clinical practice.
